

November 5, 2007

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re/ Application of Kenneth Iain Cumming and  
Zebunnissa Ramtoola  
Application No. 09/510,560  
Filed February 22, 2000  
Confirmation No. 3011

Examiner: J. Lundgren  
Art Unit 1639

**SOLID ORAL DOSAGE FORM CONTAINING AN ENHANCER**

(Attorney Docket No. P24,375-A USA)

---

**ELECTRONICALLY FILED**

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 C.F.R. 1.132 DECLARATION OF JAMES SWARBRICK D.Sc., Ph.D.**

I, James Swarbrick, D.Sc., Ph.D., declare as follows.

**POSITION AND QUALIFICATIONS**

1. I am presently a principal of PharmaceuTech, Inc., a consulting company located in Pinehurst, NC. I am expert on the formulation of active pharmaceuticals in various dosage forms and I have a thorough knowledge of the practical considerations that should be taken into account during the formation of dosage forms including tablet and capsule formulations. My Curriculum Vitae, which lists my past and present positions, duties, and publications, is attached hereto.

2. I have read and understood Irish Patent No. (11) 63119 to Bachynsky et al., and U.S. Patent No. 5,190,748 to Bachynsky et al. (collectively, “Bachynsky”), and Published PCT Application No. WO 97/05903 to Watts et al. (“Watts”), each of which have been cited in the pending Office Action.

#### PHARMACEUTICAL FORMULATIONS

3. It is generally known that a pharmaceutically active compound must be present in solution in the gastrointestinal tract (GIT) before it can pass through the epithelial cells lining the GIT wall (by any of a variety of mechanisms) and into the patient’s bloodstream.

4. In the pharmaceutical industry, drug formulations are usually developed initially as liquid formulations as these forms are the simplest to manufacture and test. However, in the development of a particular active ingredient, there is a general desire in the industry to progress from liquid formulations to solids (e.g. powder, capsule, granulate, tablet, etc.).

5. The desire to progress to solid forms can be traced to a number of advantages common to solid formulations that cannot be readily obtained by using liquids. These advantages include the following:

- ☐ Greater stability of active compounds in the solid state.
- ☐ Longer shelf life of solids over liquid formulations.
- ☐ Solid forms more tamper-evident than liquids.
- ☐ Greater dosing accuracy in solid dosage forms.
- ☐ Lower manufacturing costs for solid dosage forms
- ☐ Lower shipping, packaging, and storage costs for solid forms.

6. Various different solid formulations exist including tablets, capsules, granulates, and powders. In the pharmaceutical industry, there is a general preference for tablets over capsules, and a preference for capsules over liquid formulations. Both tablets and capsules are preferred over liquid formulations as they each provide convenient unit

dosage forms, and tablets are preferred over capsules as they are easier and less expensive to manufacture.

#### TABLETTING CONSIDERATIONS

7. Although tablets are the drug formulation of choice, the formation of tablets requires the careful manipulation of a variety of different parameters. The typical procedure for forming a pharmaceutical tablet, described in broad terms, involves: (1) forming a compressible powder or granulate blend of the tablet components; and (2) compressing an amount of the powder or granulate blend in a tablet press to form a tablet. If desired, the tablet may then be coated with a coating to modify and/or delay the release of the tablet components from the tablet. Powder or granulate blends that are to be compressed into tablets may be formed by “dry” methods, such as by the dry blending of powders or granules of the tablet components, or by “wet” methods, such as by the forming of a paste, slurry, or solution of the tablet components which is then spray dried or granulated to form a free flowing powder or granulate.

8. One important factor in the formation of tablets is that the powder or granulate blends that are to be compressed into tablets are dry, preferably free-flowing, materials. If the material is not dry, or if it is a waxy or a paste material, it does not flow freely into the tablet press and is difficult to compact into tablet. Where such material can be compacted, it is difficult to form a tablet that is properly released from the tablet press and that has the requisite structural integrity.

9. In general, the dosage forms described in Bachynsky are capsules that are filled with the mixture of a drug and a two-component enhancer system. The only disclosure of non-capsule forms is on page 7, lines 15-19 where Bachynsky mentions the possibility of forming tablets and proposes absorbing a liquid formulation onto a carrier followed by compression to form a tablet.

10. All of the drug formulations disclosed in Bachynsky include the polyoxyethylene glycol lauryl ether Laureth-12. Laureth-12 has a melting point just above room

temperature and is a soft waxy compound at room temperature. Many of the formulations in Bachynsky also contain "Witepsol H15" which is typically used as a suppository base. Notably, even the oral formulations described in Bachynsky include Witepsol H15 (for example the compositions on page 14, lines 15-19). Witepsol H15 also has a melting point just above room temperature and is also a soft waxy compound at room temperature. In view of the materials Bachynsky teaches as suitable for two-component enhancer system, the absorption enhancers that Bachynsky discloses would be considered microemulsions, a term that is generally understood to refer to stable liquid systems of water, oil, and an amphiphile.

11. All of the oral formulations in Bachynsky contain a considerable amount of these low-melting waxy compounds (e.g., Laureth-12 and Witepsol H15). For example the compositions described in the table on page 14 of Bachynsky contain between 47% and 62% (weight percent) waxy compounds. As described above, these waxy compounds make it very difficult to compress the compositions into tablets because they are soft and sticky. In my opinion, it would not be practical, and therefore not commercially viable, to form tablets by simply compressing the compositions described in Bachynsky.

12. The proposal in Bachynsky to absorb a liquid formulation onto a carrier followed by compression to form a tablet (page 7, lines 15-19) is not actually a viable proposal for the compositions described in Bachynsky. Because the compositions all contain significant amounts of a soft, low-melting material (Laureth-12 and/or Witepsol H15), a very large amount of carrier (such as silica) would be required to provide a composition dry enough to be successfully pressed into tablets. The use of such large amounts of carrier material would result in either a tablet suitable for oral administration but too small to contain a unit dose, or a unit dose tablet too large to be orally administered.

13. Furthermore, despite the statements in Bachynsky, I am not aware of any actual use in the industry of a tablet preparation process in which a solution is absorbed onto a solid carrier which is then compressed to form a tablet.

14. Watts describes a drug delivery composition including a polar drug and a two-component "absorption promoter" which can be a mixture of a fatty acid or fatty acid salt having 6-16 carbon atoms, and a dispersing agent such as Labrasol (page 5, lines 10-16). In view of the materials Watts describes as suitable for the two-component absorption promoter, the absorption enhancers that Watts discloses would be considered microemulsions. Watts also mentions, in generalized terms, formulating the compositions as tablets or pellets (page 9, lines 14-17) using "known tablet constituents and methods." The compositions in Watts are "liquid or semi-solid" depending on the length of the fatty acid carbon chain (page 8, line 21-23), and those presented in the examples of Watts are all either liquids or pastes.

15. A composition of sodium insulin and capric acid, as described in Example 3 of Watts, has been produced in accordance with the teachings of Watts. The final composition, at room temperature, is a semi-solid mass of sodium insulin and capric acid in the form of a paste.

16. In order to form tablets from any of the compositions described in Watts, it would be necessary to alter such compositions substantially in order to form a compressible powder or granulate blend. Any suggestion to absorb the liquids of Watts onto a carrier material (such as proposed in Bachynsky) suffers from the same problems noted above with respect to Bachynsky, i.e., the need for significant quantities of carrier material. Therefore, despite the reference in Watts to "known tablet constituents and methods," I am not aware of tablet constituents or methods that could be used to make commercially viable, orally administrable tablets from the compositions described in Watts.

#### DELAYED RELEASE COATINGS

17. In some circumstances, it may be desirable to apply a coating to a tablet in order to isolate the tablet components from the stomach. Such coated tablets are commonly

referred to as delayed release or enteric tablets. Delayed release tablets may be desirable where the active component in the tablet can be degraded by acidic environments, or where any of the components of the tablet may be stomach irritants. In these situations, the coating serves to isolate the tablet components from the stomach environment to avoid the undesirable stomach irritation or loss of tablet efficacy.

18. A delayed release coating may be formed from material that is a solid at room temperature and that is melted, applied in a molten state, and which then cools to form the coating. Alternatively, the coating material may be applied as a solution or suspension which is then dried to form the coating. In either case, one of the steps in the coating process (the coating step in the first case, and the drying step in the second case) is performed at elevated temperatures. As a result, the components of the tablet must be chemically and structurally stable at these elevated temperatures. Accordingly, while a tablet may be formed containing a significant amount of a component having a melting point below 50°C, it would not be possible to apply a delayed release coating to such a tablet without substantial risk of losing tablet integrity due to the melting of one or more of the components.

19. I hereby declare that all statements made herein are of my own knowledge are true, and that all statements made on information and belief are believed to be true, and further that these statements were made with knowledge that willful false statements so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application for which it is submitted and any patent issued thereon.

Dated: November 5, 2007

  
JAMES SWARBRICK D.Sc., Ph.D.

# **JAMES SWARBRICK**

## ***Curriculum Vitae***

### ***PERSONAL INFORMATION:***

Business Address: PharmaceuTech, Inc.,  
180 Doral Drive, Pinehurst, NC 28374-8682  
T: 910-255-3015; E-mail [pharmaceutech@earthlink.net](mailto:pharmaceutech@earthlink.net)

Home Address: 180 Doral Drive,  
Pinehurst, NC 28374-8682  
T: 910-255-3015; E-mail [pharmaceutech@earthlink.net](mailto:pharmaceutech@earthlink.net)

Place of Birth: London, England

Citizenship: U.S.A. (naturalized May 23, 1974, Albany, NY)

Marital Status: Married (Pamela Margaret)

Military Service: Royal Air Force, Middle East Command, 1954-56

### ***EDUCATION:***

1960	B.Pharm. (Hons), London University
1961	Ph.C. Diploma, Royal Pharmaceutical Society of Great Britain
1964	Ph.D. in Pharmaceutics, Faculty of Medicine, London University
1972	D.Sc. in Surface and Physical Chemistry, London University

### ***PROFESSIONAL BACKGROUND:***

2000-present	President, PharmaceuTech, Inc.
1999-2006	Vice President for Scientific Affairs, AAI (Applied Analytical Industries, Inc.)
1993-1999	Vice President for Research & Development, AAI
1993-present	Adjunct Professor, School of Pharmacy, University of North Carolina at Chapel Hill
1981-1993	Professor and Chairman, Division of Pharmaceutics and Director of Graduate Studies, School of Pharmacy, University of North Carolina at Chapel Hill
1978-1981	Professor of Pharmacy and Chairman, Graduate Education and Research Council, School of Pharmacy, University of Southern California
1976-1978	Dean, The School of Pharmacy, University of London, England
1975-1976	Professor of Pharmaceutics, University of Sydney, Australia
1972-1975	Director of Product Development, Sterling-Winthrop Research Institute, (Sterling Drug, Inc.), Rensselaer, N.Y.
1970-1972	Assistant Dean for Research and Graduate Studies, School of Pharmacy, University of Connecticut
1969-1972	Professor and Chairman, Pharmaceutics Division, School of Pharmacy, University of Connecticut
1966-1969	Associate Professor, School of Pharmacy, University of Connecticut
1964-1966	Visiting Assistant Professor and then Associate Professor, School of Pharmacy, Purdue University
1960-1964	Research Assistant, Assistant Lecturer and then Lecturer, Pharmacy Department, Chelsea College, London University
1960-2004	Registered Pharmacist, U.K.

**ADMINISTRATIVE AND UNIVERSITY ACTIVITIES AT UNC-CH:**

1981-1993	Director of Graduate Studies, School of Pharmacy
1981-1993	Chairman, Graduate Education and Research Committee, School of Pharmacy
1981-1989	Member, Administrative Board, School of Pharmacy
1983-1984	Chairman, Ad Hoc Committee on Faculty Code, School of Pharmacy
1984-1985	Chairman, Hearing Subcommittee for Graduate Student Petitions, UNC-CH
1984-1985	Chairman, Ad Hoc Committee on Appointment, Reappointment, and Tenure Policy, School of Pharmacy
1984-1990	Member, Administrative Board, Graduate School, UNC-CH
1984-1990	Member, Program Review Subcommittee, Graduate School, UNC-CH
1985-1986	Member, University Search Committee for Vice Chancellor of Research and Dean of the Graduate School, UNC-CH
1985-1988	Chairman, Ad Hoc Committee on Pharm D-PhD program, School of Pharmacy
1987-1988	Member, University Blue Ribbon Committee, UNC-CH
1989-1990	Member, University Search Committee for Associate Provost and Dean of the Graduate School, UNC-CH
1990-1993	Member, Biomedical Research Grants Committee, UNC-CH
1991-1993	Member, Enrollment Management Committee, UNC-CH

**NATIONAL AND INTERNATIONAL COMMITTEE APPOINTMENTS:**

1969-1971	Member, Committee on Graduate Programs, AACP
1970-1974	Member, Committee on Public Relations, Academy of Pharmaceutical Sciences
1970	Member, Committee on Undergraduate Research Awards, AACP
1970-1975	Member, Committee on Specifications, National Formulary
1971-1975	Chairman, Joint United States Pharmacopeia-National Formulary Panel on Disintegration and Dissolution Testing
1975-1976	Member, Practice Training Committee, Pharmaceutical Society of NSW, Australia
1976	Member, Therapeutic Goods and Cosmetic Advisory Committee, Health Department of New South Wales, Australia
1976-1978	Member, Education Committee, Royal Pharmaceutical Society of Great Britain
1977-1978	Member, Working Party on Pre-Registration Training for Pharmacists, Royal Pharmaceutical Society of Great Britain
1977-1978	Co-founder and first Vice Chairman, Committee of Heads of Schools of Pharmacy in the United Kingdom.
1979	Ad-Hoc Member, NIH Study Section in Pharmacology
1979-1983	Member, Resolutions Committee, Academy of Pharmaceutical Sciences
1980-1982	Member, Ebert Prize Committee, Academy of Pharmaceutical Sciences
1980-1982	Member, Volwiler Award Review Panel, AACP
1982-1990	Member, Basic Pharmacology Advisory Committee, Pharmaceutical Manufacturers Association Foundation
1984-1985	Member, US Army MRDC Advisory Subcommittee on Medical Defense Against Chemical Agents
1984-1986	Member, Research Funding Committee, Academy of Pharmaceutical Sciences
1986	Chairman Elect, North Carolina Pharmaceutical Discussion Group
1986-present	Chairman, Pharmaceuticals Advisory Committee, PhRMA Foundation
1986-present	Member, Scientific Advisory Committee, PhRMA Foundation
1996-present	Special Government Employee, FDA
1986-1989	Member, Advisory Committee, Industrial Pharmaceutical Institute, N.C. Department of Community Colleges.



**NATIONAL AND INTERNATIONAL COMMITTEE APPOINTMENTS (continued):**

1987	Chairman, North Carolina Pharmaceutical Discussion Group
1987-1988	Member, Membership Committee, Pharmaceutical Technology Section, American Association of Pharmaceutical Scientists (AAPS)
1989-1991	Chairman, Publications Committee, Pharmaceutics & Drug Delivery Section, AAPS
1989-1991	Member, Publications Committee, AAPS
1990-1996	Member, International Advisory Board, Shri B. V. Patel Pharmaceutical Education and Research Development Centre, Ahmedabad, India
1991	Member, Program Planning Committee, Pharmaceutics and Drug Delivery Section, AAPS
1991-1992	Member 1992 Arden House Planning Committee and Faculty
1992-1996	Member, Generic Drugs Advisory Committee, Food and Drug Administration (now Pharmaceutical Science Advisory Committee)
1994-1996	Chairman, Generic Drugs Advisory Committee, FDA (now Pharmaceutical Science Advisory Committee)
1996-1998	Member, Council of Chairs, Center for Drug Evaluation and Research, FDA

**CONSULTANTSHIPS:**

1965-1967	Rowell Laboratories, Baudette, Minnesota
1967-1972	Sterling-Winthrop Research Institute, Rensselaer, NY
1971	Astra Pharmaceutical Co., Sweden, Guest Scientist
1975-1976	Department of Health, Australian Government, Canberra
1975-1976	Sterling Pharmaceutical Pty. Ltd., Australia
1976-1985	Sterling-Winthrop Research and Development, U.K.
1977-1978	Science University of Malaysia, External Examiner
1977-1987	Fisons plc, Pharmaceutical Division, U.K.
1978	Organization of American States, Washington, DC
1979	Pan American Health Organization, WHO, Washington, DC
1979-1982	American Critical Care Laboratories, Chicago
1980	World Health Organization, Geneva
1981	Pan American Health Organization, Rio de Janeiro, Brazil
1981	University of El Fatah, Tripoli, Libya
1981-1982	National University of Singapore, External Examiner
1982-1985	Burroughs Wellcome Company, Research Triangle Park, NC
1987-1989	The Upjohn Company, Kalamazoo, MI
1989-1990	Becton Dickinson Research Center, Research Triangle Park, NC
1989-1991	Knowledgelink, Ltd, London, U.K.
1990-1992	Alcon Laboratories, Inc., Fort Worth, Texas
1991-1992	Intermatrix, London, U.K.
1991-1992	Adcock Ingrams, Johannesburg, South Africa
1992	Glaxo Inc, Research Triangle Park, NC
1992	Viaderm, Inc, (Member of Scientific Advisory Board) Research Triangle Park, NC
1992	General Nutrition Products, Inc., (Science Advisory Committee), Greenville, SC
1992	Smith & Nephew - Solopak, Chicago, IL
2000	Collabra Pharmaceuticals, San Francisco, CA
2000-2004	Endeavor Pharmaceuticals, Wilmington, NC
2000-2004	Genta Inc, Berkeley Heights, NJ
2001-present	Novacea, Inc., San Francisco, CA
2001-2003	Verion, Inc., Exton, PA
2002-present	Wilmington Pharmaceuticals LLC, (Member, Board of Advisors), Wilmington, NC
2003-2004	Synergia Pharma, Inc., South San Francisco, CA

**EDITORIAL ACTIVITIES AND JOURNAL REVIEWER:**

- 1964-present Served as reviewer for numerous journals, including Journal of Pharmaceutical Sciences, Journal of Pharmacy and Pharmacology, Pharmaceutical Technology, Australian Journal of Pharmaceutical Sciences, Science, Journal of Investigative Dermatology, Biopharmaceutics and Drug Disposition, Life Sciences, and International Journal of Pharmaceutics. Also Environmental Protection Agency, Lea and Febiger, John Wiley & Sons and Marcel Dekker Inc.
- 1970-1973 Series Editor, "Current Concepts in the Pharmaceutical Sciences" (2 volumes. published)
- 1973-1979 Editorial Board, "Journal of Biopharmaceutics and Pharmacokinetics"
- 1974-1981 Editorial Board, "Drug Development and Industrial Pharmacy"
- 1975-present Series Editor, "Drugs and the Pharmaceutical Sciences" (136 volumes published to date)
- 1978-1980 Editorial Board, "Pharmaceutical Technology International"
- 1978-1985 Editorial Board, "Asian Journal of Pharmaceutical Sciences"
- 1979-present Editorial Board, "Biopharmaceutics and Drug Disposition"
- 1980-present Editorial Board, "Pharmaceutical Technology"
- 1985-2005 Co-editor, "Encyclopedia of Pharmaceutical Technology" (1<sup>st</sup> and 2<sup>nd</sup> editions)
- 2005-present Editor, "Encyclopedia of Pharmaceutical Technology" (3<sup>rd</sup> edition)

**SOCIETY MEMBERSHIPS:**

- Honorary Rho Chi Pharmacy Honor Society  
Kappa Psi
- Scientific & Academy of Pharmaceutical Sciences (Elected Fellow)  
Professional Royal Society of Chemistry (Elected Fellow)  
Royal Pharmaceutical Society of Great Britain (Elected Fellow)  
American Association of Pharmaceutical Scientists (Elected Fellow)  
American Association of Colleges of Pharmacy

**HONORS AND AWARDS:**

- 1966; 1972 Awarded Lederle Pharmacy Faculty Research Award
- 1967 Awarded Mead Johnson Research Award
- 1970 Elected Fellow of the Royal Institute of Chemistry (now Royal Society of Chemistry)
- 1972 National Science Foundation-American Association of Colleges of Pharmacy  
Visiting Scientist, University of Florida and Florida A&M
- 1973 Elected Fellow of the Academy of Pharmaceutical Sciences
- 1978 Elected Fellow of the Royal Pharmaceutical Society of Great Britain
- 1978 Elected Life Member of Body Corporate, University of London School of Pharmacy
- 1988 Awarded Kenan Research Study Leave, University of North Carolina
- 1988 Visiting Professor, Brighton Polytechnic, U.K.
- 1991-1992 Visiting Professor, Shanghai Medical University, Peoples Republic of China
- also Listed in "American Men and Women of Science," "Men of Achievement," 4th edition, Debrett's "People of Today," and "Who's Who."

**MAJOR RESEARCH AND CORPORATE INTERESTS:**

Drug delivery systems - Drug availability and control of drug release from liquid, solid, and semisolid pharmaceutical dosage forms - Dosage form optimization through formulation - In vitro dissolution in relation to in vivo availability - Drug permeation through membranes, particularly human skin - Phase equilibria in multicomponent systems - Optimization of R&D organizations - Effectiveness of preformulation studies - SUPAC issues.

**RESEARCH PROPOSALS FUNDED:**

<u>Funding Source</u>	<u>Title of Proposal</u>	<u>Period of support</u>	<u>Amount awarded</u>
Purdue Res Fnd <sup>n</sup>	Ross-Ade Research Award	4/65-3/66	\$2,000
National Sci Fnd <sup>n</sup>	Instructional Scientific Equipment Pgm	5/67-4/68	\$20,800
UConn Res Fnd <sup>n</sup>	Drug Action on Model Membranes:	12/66-11/67	\$4,292
Conn Res Cms <sup>n</sup>	Water Permeation through Monolayers of Zwitterionic Amphiphiles	6/67-12/69	\$15,316
UConn Res Fnd <sup>n</sup>	Electrolyte and Water Permeation through Bimolecular Lipid Membranes	7/71-6/73	\$8,750
UConn Res Fnd <sup>n</sup>	Analog Computer model EAI-380	4/71	\$13,980
UConn Res Fnd <sup>n</sup>	Effect of Phase Equilibria on Percutaneous Drug Absorption	6/71-6/72	\$5,200
National Sci Fnd <sup>n</sup>	Undergraduate Research Summer Program	6/68-9/68	\$5,000
UConn Res Fnd <sup>n</sup>	Micellar Properties of N-Alkyl Betaines	6/67-6/68	\$5,829
Warner-Lambert Res Institute, NJ	Modification of Drug Action by Solubilization	6/67-6/69	\$10,000
Sterling-Winthrop Res Institute, NY	General Support of Research Activities	5/69-5/72	\$30,000
Bureau of Health Manpower, NIH	An Integrated Undergraduate Curriculum for Training Pharmacy Students	5/72-5/75	\$700,000
BRSG (NIH)	Biomedical Research Support Grant preparer and Program Director	4/79-3/80	\$27,000
FMC Corporation Princeton, NJ	General Support of Research Activities	7/79-6/82	\$15,000
BRSG (NIH)	Biomedical Research Support Grant preparer and Program Director	4/80-3/81	\$25,000
Fisons PLC, UK	Distribution of Cromolyn in the Rabbit Eye	9/80-8/81	\$5,500
WHO, Geneva	Intramuscular Sustained Release Formulations of Dapsone	9/80-5/83	\$60,888
Fisons PLC, UK	In Vitro Permeation Properties of Selected Chromones	5/80-6/83	\$79,375
BRSG (NIH)	Biomedical Research Support Grant	4/81-3/82	\$22,000
Cystic Fibrosis Fnd <sup>n</sup> Rockville, MD	Sustained Delivery of Amiloride to the Lung	7/84-6/86	\$49,938
NICHHD (NIH) and Family Hlth Int, RTP	D-Propranolol as a Vaginal Spermicide	10/85-9/89	\$116,649
BRSG (NIH)	Biomedical Research Support Grant preparer and Program Director	4/86-3/87	\$18,548
Fisons PLC, UK	Studies on Opticrom Viscous Eye Drops	10/86-2/87	\$3,000
BRSG (NIH)	Biomedical Research Support Grant	4/87-3/88	\$15,164

**RESEARCH PROPOSALS FUNDED (continued):**

BRSG (NIH)	Small Instrumentation Program Grant preparer and Program Director	8/87-7/88	\$5,000
Sandoz Research Institute, NJ	Development of a Skin Slab Model for Percutaneous Drug Absorption	3/88-6/91	\$76,809
Glaxo Inc and Burroughs Wellcome	Carri-Med Controlled Stress Rheometer and the Viscoelasticity of Mucus	12/88	\$33,600
BRSG (NIH)	Biomedical Research Support Grant preparer and Program Director	4/90-3/91	\$6,375
BRSG (NIH)	Biomedical Research Support Grant preparer and Program Director	4/91-3/92	\$5,000
BRSG (NIH)	Small Instrumentation Program Grant preparer and Program Director	8/91-7/92	\$5,000
US Dept of Education	Patricia Roberts Harris Graduate Study Fellowship Program (Pharm. Sciences)	8/92-7/95	\$30,000
BRSG (NIH)	Small Instrumentation Program Grant preparer and Program Director	7/92-6/93	\$5,000
BRSG (NIH)	Small Instrumentation Program Grant preparer and Program Director	7/93-6/94	\$13,677

**RESEARCH PROPOSALS APPROVED, BUT NOT FUNDED:**

US Army Med Res & Dev Cmnd	Percutaneous Absorption of Mustard and Other Substituted Ethylsulfides	6/83-6/86	\$300,603
NC Board of Sci & Technology	Percutaneous Absorption of Nicotine and its Role in Green Tobacco Sickness in NC	7/83-12/84	\$9,950

**GRADUATE STUDENTS SUPERVISED:**

<u>Name</u>	<u>University</u>	<u>Degree</u>	<u>Year Awarded</u>	<u>Major/Associate Advisor</u>
WJ McClintock	Purdue	MS	1965	Associate
AY Gore	Purdue	MS	1965	Associate
DR Powell	Purdue	MS	1965	Associate
D Fonner Jr	Purdue	MS	1965	Associate
HF Khorakiwala	Purdue	MS	1965	Associate
JW Parker	Purdue	MS	1965	Associate
GJ Baley	Purdue	MS	1966	Associate
JW Munden	Purdue	MS	1967	Major
J Daruwala	Connecticut	PhD	1968	Major
DW Blois	Connecticut	PhD	1970	Major
MA Augustine	Connecticut	PhD	1970	Major
KA Herzog	Connecticut	PhD	1970	Major
AH Amann	Connecticut	PhD	1971	Major
WH Johns	Connecticut	PhD	1971	Associate
JW Munden	Connecticut	PhD	1972	Major
AA Belmonte	Connecticut	PhD	1972	Major
AR Giaquinto	Connecticut	PhD	1972	Associate

**GRADUATE STUDENTS SUPERVISED (continued):**

RG Stoll	Connecticut	PhD	1973	Major
SA Gordziel	Connecticut	PhD	1976	Major
MS Roberts	Sydney	PhD	1976	Associate
H Nichol	Sydney	PhD	1976	Associate
TT Yang	USC	PhD	1984	Major
TM Chang	UNC	MS	1984	Major
R Henry	UNC	MS	1985	Associate
JR Siverly	USC	PhD	1986	Major
D Oakley	UNC	PhD	1986	Major
A Jamaludin	USC	PhD	1987	Major
MP Carver	NCSU	PhD	1987	Associate
MB Dorr	UNC	PhD	1988	Associate
JL Wolley	UNC	PhD	1988	Associate
O Pruksananonda	UNC	PhD	1989	Major
T Horton	UNC	MS	1989	Associate
J Jozwiakowski	UNC	MS	1990	Major
S Ruddy	UNC	PhD	1992	Associate
J. Pitts	UNC	PhD	1993	Major
T Horton	UNC	PhD	1993	Associate
K Phares	UNC	PhD	1993	Major

**POSTDOCTORAL FELLOWS TRAINED**

<u>Postdoctoral Fellow</u>	<u>Title of Project</u>	<u>Source of Support</u>	<u>Dates</u>
Dr. Geoffrey Lee	Drug Permeation through Skin	Fisons PLC	7/80-6/83
Dr. Sompol Prakongpan	Formulation of Dapsone	WHO	12/80-11/81
Dr. Keiko Suzuki	Formulation of Dapsone	WHO	9/82-6/84
" " "	Pulmonary Delivery of Amiloride	Cystic Fib Fnd	7/84-6/85
Dr. Lydia Kaus	D-Propranolol as a Spermicide	NICHD/FHI	10/85-5/87
Dr. Diane Burgess	Microspheres in Drug Delivery	Cystic Fib Fnd	12/85-6/86

## BIBLIOGRAPHY

### PEER REVIEW JOURNALS:

- Carless JE and Swarbrick J. The Oxidation of Emulsified and Solubilised Benzaldehyde. *J Pharm Pharmacol*, 14:97T-99T, 1962
- Swarbrick J and Carless JE. Phase Equilibria in Some Betaine-Benzaldehyde-Water Systems. *J Pharm Pharmacol*, 15:507-517, 1963
- Swarbrick J and Farthing CP. Theophylline Plasma Levels Following the Oral and Rectal Administration of Theophylline p-Aminobenzoate of Piperazine. *Experientia*, 19:407-408, 1963
- Carless JE and Swarbrick J. The Solubility of Benzaldehyde in Water as Determined by Refractive Index Measurements. *J Pharm Pharmacol*, 16:670-676, 1964
- Molyneux P, Rhodes CT and Swarbrick J. Thermodynamics of Micellization N-Alkyl Betaines. *Trans Faraday Soc*, 61:1043-1052, 1965
- Swarbrick J and Rhodes CT. Auto-oxidation of Linoleic Acid in Micellar Solution. *J Pharm Sci*, 54:903-906, 1965
- Swarbrick J. Solubilized Systems in Pharmacy. *J Pharm Sci*, 54:1229-1237, 1965
- McClintock WJ, Swarbrick J, Christian JE and Banker GS. Nuclear In Vitro Method of Continuously Measuring Dissolution Rates. *J Pharm Sci*, 54:1782-1786, 1965
- Fonner DE, Banker GS and Swarbrick J. Micromeritics of Granular Pharmaceutical Solids, I. *J Pharm Sci*, 55:181-186, 1966
- Fonner, DE, Banker GS and Swarbrick J. Micromeritics of Granular Pharmaceutical Solids, II. *J Pharm Sci*, 55:576-580, 1966
- Powell DR, Swarbrick J and Banker GS. Effects of Shear Processing and Thermal Exposure on the Viscosity-Stability of Polymer Solutions. *J Pharm Sci*, 55:601-605, 1966
- Banker GS, Gore AY and Swarbrick J. Water Vapour Transmission Properties of Free Polymer Films. *J Pharm Pharmacol*, 18:457-466, 1966
- Banker GS, Gore AY and Swarbrick J. Water Vapour Transmission Properties of Applied Polymer Films. *J Pharm Pharmacol*, 18:205S-211S, 1966
- Swarbrick J. Phase Equilibrium Diagrams: An Approach to the Formulation of Solubilized and Emulsified Systems. *J Soc Cosmetic Chemists*, 19:187-209, 1968
- Swarbrick J and Amann AH. Moisture Permeation through Polymer Films. *J Pharm Pharmacol*, 20:886-888, 1968
- Swarbrick J. Thermodynamics of Adsorption of N-Alkyl Betaines at the Air-Water Interface. *J Pharm Sci*, 58:147-148, 1969
- Swarbrick J and Daruwala J. Thermodynamics of Micellization of Some Zwitterionic N-Alkyl Betaines. *J Phys Chem*, 73:2627-2632, 1969
- Munden JW, Blois DW and Swarbrick J. Surface Pressure Relaxation and Hysteresis in Stearic Acid Monolayers at the Air-Water Interface. *J Pharm Sci*, 58:1308-1312, 1969
- Stoll RG, Bates TR, Nieforth KA and Swarbrick J. Some Physical Factors Affecting the Enhanced Blepharoptotic Activity of Orally Administered Reserpine-Cholanic Acid Coprecipitates. *J Pharm Sci*, 58:1457-1459, 1969.
- Augustine MA and Swarbrick J. Effect of Lipid Polarity and Cell Design on the In Vitro Transport of Salicylic Acid. *J Pharm Sci*, 59:314-317, 1970
- Swarbrick J and Daruwala J. Micellar Aggregation Properties of Some Zwitterionic N-Alkyl Betaines. *J Phys Chem*, 74:1293-1296, 1970
- Lindstrom RE and Swarbrick J. Entropy Changes Associated with Micellization. *J Phys Chem*, 74:2033, 1970
- Herzog KA and Swarbrick J. Drug Permeation through Thin Model Membranes I: Development of a Polymeric Model. *J Pharm Sci*, 59:1759-1763, 1970
- Herzog KA and Swarbrick J. Drug Permeation through Thin Model Membranes II: Permeation Characteristics of a Polymeric Model Biomembrane. *J Pharm Sci*, 60:393-395, 1971

**PEER REVIEW JOURNALS (continued):**

- Herzog KA and Swarbrick J. Drug Permeation through Thin Model Membranes III: Correlations between In Vitro Transfer, In Vivo Absorption and Physico-chemical Parameters of Substituted Benzoic Acids. *J Pharm Sci*, 60:1666-1668, 1971
- Blois DW and Swarbrick J. Some Interfacial Properties of Alkylbenzyltrimethylammonium Chlorides. *J Colloid Interface Sci*, 36:226-233, 1971
- Blois DW and Swarbrick J. Interaction of Quaternary Ammonium Bactericides with Biological Materials I: Conductometric Studies with Cephalin. *J Pharm Sci*, 61:390-392, 1972
- Blois DW and Swarbrick J. Interaction of Quaternary Ammonium Bactericides with Biological Materials II: Insoluble Monolayer Studies. *J Pharm Sci*, 61:393-399, 1972
- Augustine MA and Swarbrick J. Correlation between In Vitro Transport in a Three-Phase Model Cell and In Vitro Absorption of a Series of Sulfonamides. *J Pharm Sci*, 61:1656-1658, 1972
- Swarbrick J, Amann AH and Lindstrom RE. Factors Affecting Water Vapor Transmission through Free Polymer Films. *J Pharm Sci*, 61:1645-1647, 1972
- Belmonte AA, Swarbrick J, Jensen RG and Gordon DT. Biological Implications of Cadmium-Phospholipid Monolayers. *Lipids*, 7:490-492, 1972
- Swarbrick J, Galownia J and Bates TR. Micellar Solubilization of Orange OT by a Series of N-Alkyl Betaines. *J Colloid Interface Sci*, 41:609-611, 1972
- Stoll RG, Bates TR and Swarbrick J. In Vitro Dissolution and In Vivo Absorption of Nitrofurantoin from Deoxycholic Acid Coprecipitates. *J Pharm Sci*, 62:65-68, 1973
- Munden JW and Swarbrick J. Time-Dependent Surface Behaviour of Dipalmitoyl Lecithin and Lung Alveolar Surfactant Monolayers. *Biochem Biophys Acta*, 291:344-350, 1973
- Belmonte AA and Swarbrick J. Interaction of Cholesterol with Dibenzanthracenes at Air-Water Interface. *J Pharm Sci*, 62:481-483, 1973
- Munden JW and Swarbrick J. Effect of Spreading Solvent on the Monolayer Characteristics of Dipalmitoyl Lecithin. *J Colloid Interface Sci*, 42:657-659, 1973
- Belmonte AA and Swarbrick J. Surface Behaviour of Dibenzanthracene with Lipid Monolayers. *Biochem Biophys Acta*, 323:647-653, 1973
- Amann AH, Lindstrom RE and Swarbrick J. Factors Affecting Water Vapor Transmission through Polymer Films Applied to Solid Surfaces. *J Pharm Sci*, 63:931-933, 1974
- Swarbrick J. Drug Dissolution Testing: Today and Tomorrow. *Drug Dev Comm*, 2:429-438, 1976
- Swarbrick J. The Role of Model Systems in Assessing Bioavailability of Orally Administered Drugs. *Drug Dev Comm*, 2:439-451, 1976
- Swarbrick J. Drug Delivery Systems of the Future. *Aust J Pharm Sci*, NS 5:73-77, 1976
- Roberts MS, Anderson RA, Moore DE and Swarbrick J. The Distribution of Non-Electrolytes between Human Stratum Corneum and Water. *Aust J Pharm Sci*, 6:77-82, 1977
- Giaquinto AR, Lindstrom RE, Swarbrick J and LoSurdo A. Amide-Water Interactions in Cosolvent Systems. I. Solubilities and Apparent Molar Volumes of Methyl Paraben. *J Solution Chemistry*, 6:687-701, 1977
- Roberts MS, Anderson RA and Swarbrick J. Permeability of Human Epidermis to Phenolic Compounds. *J Pharm Pharmacol*, 29:677-683, 1977
- Roberts MS, Anderson RA, Swarbrick J. The Percutaneous Absorption of Phenolic Compounds: The Mechanism of Diffusion Across the Stratum Corneum. *J Pharm Pharmacol*, 30:486-490, 1978
- Swarbrick J and Ma D. In Vitro Dissolution of Dapsone. *J Pharm Pharmacol*, 33:787-789, 1981
- Swarbrick J and Stoll RE. Organization within the Pharmaceutical Industry - A Survey. *Drug Dev Ind Pharm*, 7:633-644, 1981
- Gordziel SA, Flanagan DR and Swarbrick J. Interaction of Monomolecular Films of Biological Significance with Heavy Metal Ions and Complexes at the Air-Water Interface, I: Stearic Acid and Zinc, Cadmium and Mercury. *J Colloid Interface Sci*, 86:178-184, 1982
- Swarbrick J, Lee GWJ and Brom J. Drug Permeation through Human Skin I: Effect of Storage Conditions of Skin. *J Invest Dermatol*, 78:63-66, 1982

**PEER REVIEW JOURNALS (continued):**

- Lee VHL, Swarbrick J, Stratford RE and Morimoto KW. Disposition of Topically Applied Sodium Cromoglycate in the Albino Rabbit Eye, *J Pharm Pharmacol*, 35:445-450, 1983
- Lee VHL, Swarbrick J, Redell MA and Yang DC. Vehicle Influence on Ocular Disposition of Sodium Cromoglycate in the Albino Rabbit, *Int J Pharmaceutics*, 16:163-170, 1983
- Swarbrick J, Lee G, Brom J and Gensmantel, NP. Drug Permeation through Human Skin II: Permeability of Ionizable Compounds. *J Pharm Sci*, 73:1352-1355, 1984
- Swarbrick J and Shrewsbury RP. The Prolonged Retention of Sodium Cromoglycate in the Rabbit Eye. *J Pharm Pharmacol*, 36:121-122, 1984
- Lee G, Swarbrick J, Kiyohara G and Payling, DW. Drug Permeation through Human Skin III: Effect of pH on the Partitioning Behavior of a Chromone-2-Carboxylic Acid. *Int J Pharmaceutics*, 23:43-54, 1985
- Shrewsbury RP, Swarbrick J, Newton KS and Riggs LC. Influence of Ophthalmic Formulations on DSCG Retention in the Rabbit Eye. *J. Pharm Pharmacol*, 37:614-617, 1985
- Yang TT and Swarbrick J. Sustained Release Delivery Systems. I, Phase Diagram Studies of Dapsone and Selected Derivatives. *J. Pharm Sci*, 75:53-56, 1986
- Yang TT and Swarbrick J. Sustained Release Delivery Systems II, In Vitro Dissolution of 4,4'-Sulfonylbisbenzamine (Dapsone)-N-Dodecanoyl- 4,4'-Sulfonylbisbenzamine Comelts. *J Pharm Sci*, 75:264-270, 1986.
- Swarbrick J, Prakongpan S and Suzuki K. Sustained Release Delivery Systems. III, Preparation and In Vitro Dissolution of Surface Reacted Dapsone Particles. *Int J Pharmac*, 32:21-29, 1986.
- Oakley DM and Swarbrick J. The Effects of Ionization on the Percutaneous Absorption of Drugs: The Partitioning of Nicotine into Organic Liquids and Hydrated Stratum Corneum. *J Pharm Sci*, 76, 866-871, 1987.
- Swarbrick J. and Siverly JR. The Influence of Liquid Crystalline Phases on Drug Percutaneous Absorption: I. Development of a Vehicle. *Pharm. Res*, 9, 1546-1549, 1992.
- Swarbrick J. Do Processing and Scale-Up Factors Really Affect Bioavailability? - A Suggestion for Answering the Question. *Pharm. Tech*, 15th Anniversary Issue, 32-36, 1992
- Swarbrick J and Siverly JR. The Influence of Liquid Crystalline Phases on Drug Percutaneous Absorption: II. Permeation Studies through Excised Human Skin. *Pharm. Res*, 9, 1550-55, 1992.
- Rubino PO, Kowalsky R and Swarbrick J. Albumin Microspheres as a Drug Delivery System: Relation Among Turbidity Ratio, Degree of Cross-linking, and Drug Release. *Pharm. Res*, 10, 1059-1065, 1993.
- Phares K, Cho M, Johnson K and Swarbrick J. Drug Transport across Nylon 610 Films: Influence of Synthesis Variables. *Pharm. Res*, 12, 248-256, 1995.
- Greaves FC, Beasley MW, Suddith AW and Swarbrick J. Novel Approaches to the Preparation of Low Dose Solid Dosage Forms. *Pharm. Tech*, 19, 60-64, 1995.
- Chattaraj SC, Swarbrick J and Kanfer I. A Simple Diffusion Cell to Monitor Drug Release from Semisolid Dosage Forms. *International Journal of Pharmaceutics*, 120, 119-124, 1995.
- Kanfer I, Brown C, Konings M and Swarbrick J. Absorption of Sulindac from a Novel (Pro-Sorb™) Liquid Formulation. *Biopharmaceutics & Drug Disposition*, 17, 209-221, 1996.
- Phares K, Cho, M, Swarbrick J, Wallace A and Johnson K. Drug Release from Oil-Containing Microcapsules: I. Mathematical Model Development. *International Journal of Pharmaceutical Advances*, 1, 357-376, 1996.
- Phares K, Cho, M, Swarbrick J, Wallace A and Johnson K. Drug Release from Oil-Containing Microcapsules: II. Release Data. *International Journal of Pharmaceutical Advances*, 1, 377-390, 1996.
- Swarbrick J. Advances in Controlled Drug Delivery. *S.T.P. Pharma Pratiques*, 6 (1), 53-60, 1996.
- Swarbrick J. In Vitro Dissolution, Drug Bioavailability, and the Spiral of Science. *Pharmaceutical Technology*, 21, 68-72, 1997.



**PEER REVIEW JOURNALS (continued):**

- Swarbrick J. Recent Developments in Dissolution testing and Data Correlation. *Pharmaceutical Technology Europe*, September issue, 55-58, 1997.
- Swarbrick J. Recent Developments in Dissolution testing and Data Correlation. *Pharmaceutical Technology Asia*, September/October issue, 25-26, 1997.
- Flynn GL, Shah VP, Tenjarla SN, Corbo M, DeMagistris D, Feldman TG, Franz TJ, Mirna DR, Pearce DM, Sequeira JA, Swarbrick J, Wang JCT, Yacobi A, and Zatz JL. Assessment of Value and Applications of In Vitro Testing of Topical Dermatological Drug Products. *Pharmaceutical Research*, 16, 1325-1330, 1999.
- Peroutka SJ, Lyon JA, Swarbrick J, Lipton RB, Kolodner K, and Goldstein J. A Randomized, Double-Blind, Crossover Study of the Efficacy of 100 mg Diclofenac Sodium Softgel Formulation with or without 100 mg Caffeine in the Acute Treatment of Migraine without Aura, *Headache*, 44, 136-141, 2004.
- Zuniga JR, Phillips C, Shugars D, Rogers L, Lyon J, Peroutka S, and Swarbrick J. Analgesic Safety and Efficacy of Diclofenac Sodium Softgels in Postoperative Dental Pain, *J Oral Maxillofac Surg*, 62, 806-815, 2004.

**DISSERTATION, PUBLISHED ABSTRACTS AND PRESENTATIONS:**

- Swarbrick J. Oxidation Studies of Soap-Water-Aldehyde Dispersions. *PhD Dissertation, University of London*, 1964
- Swarbrick J and Rhodes CT. The Autoxidation of Linoleic Acid in Micellar Solution. *Abstracts of the 112th Annual Meeting of the APhA*, Detroit, Michigan, p 52, 1965
- Powell DR, Swarbrick J and Banker GS. The Effects of Shear Processing and Thermal Exposure on the Viscosity-Stability of Polymer Solutions. *Abstracts of the 113th Annual Meeting of APhA*, Dallas, Texas, p 41, 1966
- Fonner DE, Banker GS and Swarbrick J. Micromeritics of Granular Pharmaceutical Solids, II: Factors Involved in the Sieving of Pharmaceutical Granules. *Abstracts of the 113th Annual Meeting of the APhA*, Dallas, Texas, p 41, 1966
- Swarbrick J. Thermodynamics of Adsorption of N-Alkyl Betaines at the Air-Water Interface. *Abstracts of the 115th Annual Meeting of the APhA*, Miami Beach, Florida, p 69, 1968
- Stoll RG, Bates TR, Nieforth KA and Swarbrick J. Mechanism of Bile Acid Enhancement of Orally Administered Drugs. *Abstracts of the 115th Annual Meeting of the APhA*, Miami Beach, Florida, p 110, 1968
- Munden JW, Blois DW and Swarbrick J. Surface Pressure Relaxation and Hysteresis in Stearic Acid Monolayers at the Air-Water Interface. *Abstracts of the 116th Annual Meeting of the APhA*, Montreal, Canada, p 44, 1969
- Swarbrick J, Galownia J and Bates TR. Micellar Solubilization of a Water-Insoluble Dye by a Series of N-Alkyl Betaines. *Abstracts of the 116th Annual Meeting of the APhA*, Montreal, Canada, p 50, 1969
- Augustine MA and Swarbrick J. Effect of Lipid Polarity on In Vitro Transport of Salicylic Acid. *Abstracts of the 116th Annual Meeting of the APhA*, Montreal, Canada, p 53, 1969
- Herzog KA and Swarbrick J. Drug Transport Across Thin Model Membranes II. Some Transport Characteristics of a Polymeric Model Membrane. *Abstracts of the 117th Annual Meeting of the APhA*, Washington, DC, p 51, 1970
- Stoll RG, Bates TR and Swarbrick J. In Vitro Dissolution and In Vivo Absorption of Nitrofurantoin from Deoxycholic Acid Coprecipitates. *Abstracts of the 118th Annual Meeting of the APhA*, San Francisco, California, 1(1), 56, 1971
- Blois DW and Swarbrick J. The Action of Surface Active Bactericides on Simulated Bacterial Cell Walls. *Abstracts of the 118th Annual Meeting of the APhA*, San Francisco, California, 1(1) 62, 1971

**DISSERTATION, PUBLISHED ABSTRACTS AND PRESENTATIONS (continued):**

- Augustine MA and Swarbrick J. Correlations Between In Vitro Drug Transport and In Vivo Drug Absorption Using a Three-Phase Model Cell. *Abstracts of the 118th Annual Meeting of the APhA*, San Francisco, California, 1(1) 77, 1971
- Herzog KA and Swarbrick J. Drug Permeation Across Thin Model Membranes III. Correlation Between In Vitro Transfer, Certain Physico-chemical Parameters and In Vivo Absorption of Some Substituted Benzoic Acids. *Abstracts of the 118th Annual Meeting of the APhA*, San Francisco, California, 1(1) 77, 1971
- Belmonte AA and Swarbrick J. The Interaction of Cholesterol with Dibenzanthracenes at the Air-Water Interface. *Abstracts of the 119th Annual Meeting of the APhA*, Houston, Texas, 2(1) 68, 1972
- Belmonte AA and Swarbrick J. Surface Behavior of Dibenzanthracene with Lipid Monolayers. *Abstracts of the 15th National Meeting of the Academy of Pharmaceutical Sciences*, San Diego, California, 3(2) 53, 1973
- Gordziel SA and Swarbrick J. Interactions of Cadmium, Zinc and Mercury Ions with Monolayers of Dipalmitoyl Phosphatidyl Choline. *Abstracts of the 17th National Meeting of the Academy of Pharmaceutical Sciences*, New Orleans, Louisiana, 4(2) 133, 1974
- Swarbrick J. Drug Dissolution Testing: Today and Tomorrow. *Abstracts of the 122th Annual Meeting of the APhA*, San Francisco, California, 5(1) 53, 1975
- Swarbrick J. Organization Within The Pharmaceutical Industry. *Abstracts of the 128th Annual Meeting of the APhA*, St. Louis, Missouri, 11(1), 36, 1981
- Swarbrick J and Prakongpan S. Intramuscular Sustained Release Dosage Forms, I: Surface Reaction Technique Applied to Dapsone. *Abstracts of the 31st National Meeting of the Academy of Pharmaceutical Sciences*, Orlando, Florida, 11(2) 895, 1981
- Swarbrick J and Lee G. Drug Permeation Through Human Skin II: Effect of pH on the Permeation of Chromone-2-Carboxylic Acids. *Abstracts of the 31st National Meeting of the Academy of Pharmaceutical Sciences*, Orlando, Florida, 11(2): 95, 1981
- Lee VHL, Swarbrick J, Stratford RE and Morimoto KI. Disposition of Topically Applied Sodium Cromoglycate in the Albino Rabbit. *Abstracts of the 33rd National Meeting of the Academy of Pharmaceutical Sciences*, San Diego, California, 12(2): 128, 1982
- Lee VHL, Swarbrick J, Redell MA and Yang DC. Vehicle Influence on Ocular Bioavailability of Sodium Cromoglycate in the Albino Rabbit. *Abstracts of the 33rd National Meeting of the Academy of Pharmaceutical Sciences*, San Diego, California, 12(2): 128, 1982
- Lee G, Swarbrick J and Kiyohara G. Drug Permeation Through Human Skin III: Effect of pH on the Partitioning Behavior of a Chromone-2-Carboxylic Acid. *Abstracts of the 33rd National Meeting of the Academy of Pharmaceutical Sciences*, San Diego, California, 12(2): 130, 1982
- Yang TT and Swarbrick J. Dapsone-Monolauryl Dapsone Solid Dispersions: Determination of Phase Diagram and Effect of Dissolution. *Abstracts of the 130th APhA Annual Meeting, Academy of Pharmaceutical Sciences*, New Orleans, Louisiana, 13(1): 30, 1983
- Siverly J and Swarbrick J. An HPLC Assay to Determine Non-chromophoric Alcohols and Non-ionic Surfactants in Ternary Alcohol-Surfactant-Water Systems. *Abstracts of the 130th APhA Annual Meeting, Academy of Pharmaceutical Sciences*, New Orleans, Louisiana, 13(1): 84, 1983
- Swarbrick J, Lee G and Porter K. Drug Permeation Through Human Skin IV: The Partitioning Behavior of a Series of Chromone Esters and their Parent Acid. *Abstracts of the 131st APhA Annual Meeting, Academy of Pharmaceutical Sciences*, Montreal, Canada, 14(1): 58, 1984
- Swarbrick J, Lee G and Wright B. Drug Permeation Through Human Skin V: Permeation of a Series of Chromone Esters and their Parent Acid. *Abstracts of the 131st APhA Annual Meeting, Academy of Pharmaceutical Sciences*, Montreal, Canada, 14(1): 58, 1984
- Shrewsbury RP, Swarbrick J, Newton K and Riggs L. The Retention of Topically Applied Sodium Cromoglycate in the Albino Rabbit Eye. *Abstracts of the 131st APhA Annual Meeting, Academy of Pharmaceutical Sciences*, Montreal, Canada, 14(1): 69, 1984

**DISSERTATION, PUBLISHED ABSTRACTS AND PRESENTATIONS (continued):**

- Oakley D and Swarbrick J. The Percutaneous Absorption of Nicotine. *5th Annual GRASP meeting*, Rutgers Univ., July 1984
- Oakley D and Swarbrick J. The Partitioning of Nicotine into Stratum Corneum and Selected Organic Liquids. *Abstracts of the 132nd APhA Annual Meeting, Academy of Pharmaceutical Sciences*, San Antonio, Texas, 15(1): 78, 1985
- Oakley D and Swarbrick J. The Ion-Pair Partitioning and Protein Binding of Nicotine in Stratum Corneum. *Abstracts of the 39th National Meeting of the Academy of Pharmaceutical Sciences*, Minneapolis, Minnesota, 15(2): 77, 1985
- Oakley D and Swarbrick J. Thermodynamics of the Partitioning of Nicotine in Organic Liquids and Stratum Corneum. *Abstracts of the 1st Annual Meeting, AAPS*, Washington, DC, Pharm. Res., 3, 495, 1986
- Pruksananonda O, Kowalsky RJ, and Swarbrick J. Turbidity as an Indicator of Crosslinking in Albumin Microspheres. *Abstracts of the JUC-Pharm Sci Meeting*, Honolulu, Hawaii, J. Pharm. Sci., 76, S292, 1987
- Pruksananonda O, Kowalsky RJ, and Swarbrick J. Validity of Turbidity Method as an Indication of Crosslinking in Albumin Microspheres. *Abstracts of the 3rd Annual Meeting, AAPS*, Orlando, Florida, Pharm. Res., 5, S50, 1988
- Swarbrick J and Marriott C. The Effect of Potential Spermicides on the Viscoelasticity of Mucus. *Abstracts of the 3rd Annual Meeting, AAPS*, Orlando, Florida, Pharm. Res., 5, S-92, 1988
- Pitts J and Swarbrick J. An In Vitro Skin Slab Model for Percutaneous Absorption. *Abstracts of 9th Annual GRASP Meeting*, Athens, Georgia, June 1989
- Pitts J and Swarbrick J. An In Vitro Skin Slab Method for Percutaneous Absorption Studies. *Abstracts of the 4th Annual Meeting, AAPS*, Atlanta, Georgia, Pharm. Res., 6, S-174, 1989
- Pari JH and Swarbrick J. A Model System for Studying the Viscoelasticity of Mucus. *Abstracts of the 4th Annual Meeting, AAPS*, Atlanta, Georgia, Pharm. Res., 6, S-152, 1989
- Pruksananonda O, Kowalsky RJ, and Swarbrick J. Relationship between the Turbidity Ratio and the Release of Amiloride from Albumin Microspheres. *Abstracts of the 4th Annual Meeting, AAPS*, Atlanta, Georgia, Pharm. Res., 6, S-102, 1989
- Pitts J and Swarbrick J. An In Vitro Skin Slab Model for Percutaneous Absorption Studies. *Abstracts of 10th Annual GRASP meeting*, Chapel Hill, NC, June 1990
- Jozwiakowski, JP and Swarbrick J. Development of a Model System for Studying the Viscoelasticity of Mucus. *Abstracts of 10th Annual GRASP meeting*, Chapel Hill, NC, June 1990
- Pitts J, Kanfer I, and Swarbrick J. Percutaneous Absorption of Estradiol Using In Vitro Skin Slabs. *Abstracts of the 5th Annual Meeting, AAPS*, Las Vegas, Nevada, Pharm. Res., 7, S-186, 1990.
- Jozwiakowski JP, Kanfer I, and Swarbrick J. Effects of Calcium and Bile Salt on the Viscoelasticity of a Model Mucus System. *Abstracts of the 5th Annual Meeting, AAPS*, Las Vegas, Nevada. Pharm. Res., 7, S-204, 1990.
- Kanfer I and Swarbrick J. Semi-Micro In Vitro Method for the Measurement of Release Rates of Diclofenac from Semi-Solid Dosage Forms. *South African Academy of Pharmaceutical Sciences Congress*, Durban, South Africa, April 1991.
- Pitts J and Swarbrick J. Determination of Estradiol in Various Skin Layers after Topical Application in Three Different Vehicles. *Abstracts of the 11th Annual GRASP Meeting*, Pittsburgh, PA, May 1991
- Pitts J and Swarbrick J. The Distribution of Estradiol within the Layers of Hairless Guinea Pig Skin. *Abstracts of the 6th Annual Meeting, AAPS*, Washington, D.C. Pharm. Res., 8, S-203, 1991.
- Phares KR, Cho MJ, Johnson KA and Swarbrick J. Drug Transport across Nylon 610 Films: Influence of Synthesis Variables. *Abstracts of the 7th Annual Meeting, AAPS*, San Antonio, TX. Pharm. Res., 9, S-176, 1992.

**DISSERTATION, PUBLISHED ABSTRACTS AND PRESENTATIONS (continued):**

- Pitts J and Swarbrick J. Assessment of Estradiol Distribution In Vivo and Partitioning In Vitro as a Function of Dermal Depth. *Abstracts of the 7th Annual Meeting, AAPS, San Antonio, TX. Pharm. Res.*, 9, S-237, 1992
- Phares KR, Ambrose W, Cho MJ, Johnson KA and Swarbrick J: Drug Release from Oil-Containing Microcapsules. *Abstracts of the 8th Annual Meeting, AAPS, Orlando, FL. Pharm. Res.*, 10, S-275, 1993.
- Kanfer I, Brown C, Konings M and Swarbrick J. Bioequivalence of a Generic Terfenadine Tablet with Two Non-Bioequivalent Innovator Tablets. *Abstracts of the 10th Annual Meeting, AAPS, Miami, FL. Pharm.Res.*, 12, S-240, 1995.
- Kanfer I, Brown C, Konings M and Swarbrick J. Effect of Pro-Sorb™ Approach on the Rate and Extent of Absorption of Sulindac. *Abstracts of the 10th Annual Meeting, AAPS, Miami, FL. Pharm.Res.*, 12, S-240, 1995.
- Sinar DR, Ellis P, Beasley M, Hong D and Swarbrick J. Gastric Irritant Potential of Pro-Sorb™ Liquid Sulindac and Clinoril Tablets in the Monkey. *Abstracts of the 10th Annual Meeting, AAPS, Miami, FL. Pharm.Res.*, 12, S-108, 1995.
- Kanfer I, Brown C, Konings M and Swarbrick J. Effect of Pro-Sorb™ Approach on the Rate of Oral Absorption of Diclofenac. *Abstracts of the 12th Annual Meeting, AAPS, Boston, MA. Pharm.Res.*, 14, S-654, 1997.
- Swarbrick J, Lomartire K and Fenzl E. The Role of Rapidly Absorbed Non-Steroidal Anti-Inflammatory Agents in the Abortive Treatment of Migraine. *Abstracts of the 40<sup>th</sup> Annual Scientific Meeting of the American Association for the Study of Headache*, San Francisco, CA, p. 180, 1998.
- Swarbrick J, Lyon JA and Peroutka SJ. Effect of Metoclopramide and Caffeine on the Rapid Oral Absorption of Diclofenac. *Headache World 2000 Abstracts, Cephalalgia*, 20, 341, 2000.
- Zuniga, JR, Phillips C, Shugars D, Lyon J, Peroutka S, and Swarbrick J. Analgesic Safety and Efficacy of Diclofenac Sodium Softgels in Postoperative Dental Pain. *J Oral Maxillofac Surg (Suppl 1)*, 59, 62, 2001.
- Zuniga, JR, Phillips C, Shugars D, Lyon J, Peroutka S, and Swarbrick J. Analgesic Safety and Efficacy of Diclofenac Sodium Softgels in Postoperative Dental Pain. *Abstracts of American College of Clinical Pharmacy Meeting*, Savannah, GA, April 2002.

**BOOKS:**

- Martin AN, Swarbrick J and Cammarata A. *Physical Pharmacy*, 2<sup>nd</sup> edition, Lea & Febiger, Philadelphia, pp 637, 1969
- Swarbrick J. *Current Concepts in the Pharmaceutical Sciences: Biopharmaceutics*, Lea & Febiger, Philadelphia, pp 304, 1970
- Swarbrick J. *Current Concepts in the Pharmaceutical Sciences: Dosage Form Design and Bioavailability*, Lea & Febiger, Philadelphia, pp 230, 1973
- Martin AN, Swarbrick J and Cammarata A. *Physical Pharmacy*, 3<sup>rd</sup> edition, Lea & Febiger, Philadelphia, 1983
- Swarbrick J and Boylan JC. *Encyclopedia of Pharmaceutical Technology*, 1<sup>st</sup> Edition, Marcel Dekker Inc, New York, published in 20 volumes, 1998-2001
- Swarbrick J and Boylan JC. *Encyclopedia of Pharmaceutical Technology*, 2<sup>nd</sup> Edition, Marcel Dekker Inc, New York, published in 3 volumes and electronically, 2002
- Hillary AM, Lloyd AW and Swarbrick J. *Drug Delivery and Targeting -- For Pharmacists and Pharmaceutical Scientists*, Taylor and Francis, London, 2002

**SERIES EDITORSHIP:**

Sole series editor for "*Drugs and the Pharmaceutical Sciences*," a series of textbooks and monographs published by Marcel Dekker, Inc., New York, 159 volumes published to date since 1975

**CHAPTERS IN BOOKS:**

- Martin AN and Swarbrick J. *Colloidal Dispersions*. In *American Pharmacy*, Chapter 7, 6<sup>th</sup> edition, Lippincott, Philadelphia, 1969
- Swarbrick J and Martin AN. *Coarse Dispersions*. In *American Pharmacy*, Chapter 8, 6<sup>th</sup> edition, Lippincott, Philadelphia, 1969
- Swarbrick J. *Emulsions and Suspensions*. *Remington's Pharmaceutical Sciences*, Chapter 22, 14<sup>th</sup> edition, Mack Publishing, Philadelphia, 1969
- Swarbrick J. *In Vitro Models of Drug Dissolution*. In *Current Concepts in the Pharmaceutical Sciences: Biopharmaceutics*, Chapter 6, Lea & Febiger, Philadelphia, 1970
- Swarbrick J. *Coarse Dispersions*. In *American Pharmacy*, Chapter 7, 7<sup>th</sup> edition, Lippincott, Philadelphia, 1974
- Swarbrick J. *Emulsions and Suspensions*. In *Remington's Pharmaceutical Sciences*, Chapter 22, 15<sup>th</sup> edition, Mack Publishing, Philadelphia, 1974
- Higuchi WI, Swarbrick J, HO NFH, Simonelli AP and Martin AN. *Particle Phenomena and Coarse Dispersions*. In *Remington's Pharmaceutical Sciences*, Chapter 21, 16<sup>th</sup> edition, Mack Publishing, Philadelphia, 1980
- Higuchi WI, Swarbrick J, Ho NFH, Simonelli and Martin AN. *Particle Phenomena and Coarse Dispersions*. In *Remington's Pharmaceutical Sciences*, Chapter 21, 17<sup>th</sup> edition, Mack Publishing, Philadelphia, 1985
- Zografis G, Schott H and Swarbrick J. *Interfacial, Colloidal and Particle Phenomena*. In *Remington's Pharmaceutical Sciences*, Chapter 19, 18<sup>th</sup> ed, Mack Publishing, Philadelphia, 1990
- Swarbrick J. *Coarse Dispersions*. In *Remington's Pharmaceutical Sciences*, Chapter 21, 19<sup>th</sup> edition, Mack Publishing, Philadelphia, 1995
- Swarbrick J, Rubino J and Rubino O. *Coarse Dispersions*. In *Remington's Pharmaceutical Sciences*, Chapter 21, 20<sup>th</sup> edition, Mack Publishing, Philadelphia, 1998

**PATENTS:**

- Swarbrick J. Prolonged Action Drug Formulation. *US Patent No. 4,461,776*, July 17, 1984
- Swarbrick J. Prolonged Action Drug Formulation. *US Patent No. 4,731,359*, March 15, 1988
- Greaves FC, Swarbrick J, Beasley MW, Suddith AW. Method for Preparing Low Dose Pharmaceutical Products, *South African Patent No. 93/9565*, September 28, 1994
- Greaves FC, Swarbrick J, and Beasley, MW. Method for Dry Blend Compression of Medicaments. *South African Patent No. 93/9566*, September 28, 1994
- Leonard TW, Hause DP, Sancilio FD, Swarbrick J and Wilson ES. Oral Compositions of H<sub>2</sub> Antagonists. *US Patent No. 5,538,737*, July 23, 1996
- Greaves FC, Swarbrick J, and Beasley, MW. Method for Dry Blend Compression of Medicaments. *US Patent No. 5,928,668*, July 27, 1999
- Greaves FC, Swarbrick J, Beasley MW, Suddith AW, Caldwell HC. Method for Preparing Low Dose Pharmaceutical Products, *US Patent 5,976,570*, November 2, 1999

**OTHER ARTICLES and BOOK REVIEWS:**

- Swarbrick J. Pharmacy Graduate Education in the USA. *Pharm J*, 199: 14-16, 1967
- Swarbrick J. An Integrated Program for Training Pharmacy Students. *Am J Pharm Educ*, 35: 185-190, 1971
- Swarbrick J. Delivering Medicines on Target. *Assoc Brit Pharm Ind News*, 165: 6, April 1977
- Swarbrick J. Monthly article entitled "London Letter" in *Australian J Pharmacy*, December 1976-July 1978
- Swarbrick J. Monthly article entitled "Letter from California" in *Australian J Pharmacy*, August 1978-February 1980 and occasionally thereafter
- Bectel MQ and Swarbrick J. The PMA Foundation: A New Program for Pharmaceuticals. *Pharm Tech*, 10(10):56-60, 1986
- Nonionic Surfactants, Vol 1, Marcel Dekker Inc. Reviewed in *J Pharm Sci*, 56: 663, 1967
- Cationic Surfactants, Vol 2, Marcel Dekker Inc. Reviewed in *J Pharm Sci*, 59: 1365, 1970
- Introduction to Biopharmaceutics, Lea & Febiger. Reviewed in *J Pharm Sci*, 61: 654, 1972
- Advances in the Pharmaceutical Sciences, Vol 4, Academic Press. Reviewed in *Aust J Pharm Sci*, NS5: 96, 1975
- Clinical Pharmacy Sourcebook. Reviewed in *Modern Medicine*, 1976
- Principles and Perspectives in Drug Bioavailability, Karger. Reviewed in *Pharmaceutical Technology*, 3(6): 165, 197- Controlling the Use of Therapeutic Drugs, American Enterprise Institute. Reviewed in *Pharmaceutical Technology*, 4(1): 96, 1980
- Biopharmaceutics and Drug Interactions, Raven Press. Reviewed in *Pharmaceutical Technology*, 8(2): 69, 1984
- Clarke's Isolation and Identification of Drugs, Pharmaceutical Press. Reviewed in *J. Pharm Sci*, 76:420, 1987

**INVITED SPEAKER, SEMINARS PRESENTED:**

- Abbott Laboratories, Chicago. *Phase Equilibrium Diagrams: A Systemic Approach to the Formulation of Solubilized and Emulsified Systems*, April 1965
- Purdue University, Professional Pharmacy Clinic. *National Health Services in Britain*, April 1965
- Pfizer Laboratories, Brooklyn, NY. *Formulation of Coarse Dispersions*, June 1966
- Society of Cosmetic Chemists, Annual Meeting, New York. *Phase Equilibrium Diagrams*, May 1967
- Sterling-Winthrop Research Institute, Rensselaer, NY. *Particle Size Control in Pharmaceutical Dosage Forms*, October 1967
- Albany College of Pharmacy, Albany, NY. *Bioavailability of Oral Dosage Forms*, May 1968
- Merck Sharp & Dohme Laboratories, West Point, PA. *Factors Influencing Drug Permeation Across Biological Membranes*, September 1968
- Warner-Lambert Research Institute, Morris Plains, NJ. *Design and Evaluation of a Three Phase Model System for Drug Transport*, October 1968
- University of Connecticut, Continuing Education Program. *Basic Concepts of Biopharmaceutics*, October 1968
- New Hampshire Pharmaceutical Association, Concord, NH. *Biopharmaceutics of Oral Contraceptives*, June 1969
- Ciba Laboratories, Summit, NJ. *Drug Stability in Heterogeneous Dispersions*, September 1969
- Columbia University College of Pharmaceutical Sciences, New York, NY. *In Vitro Models of Dissolution Testing*, May 1970
- Merck Sharp & Dohme Laboratories, Hoddesdon, UK. *The Status of Dissolution Testing in the USA*, July 1970
- Ciba Laboratories, Summit, NJ. *Dissolution Testing*, September 1970
- Sterling-Winthrop Research Institute, Rensselaer, NY. *Increasing the Absorption of Selected Drugs*, November 1970

**INVITED SPEAKER, SEMINARS PRESENTED (continued):**

- Astra Pharmaceutical Company, Sodertalje, Sweden. *Series of five lectures on Drug Dissolution and Absorption*, July-August 1971
- Swedish Institute for Surface Chemistry, Stockholm. *Use of the Film Balance to Study Molecular Interactions at Interfaces*, August 1971
- Swedish Pharmaceutical Society, Stockholm. *Drug Transport and Dissolution*, September 1971
- University of Florida, Gainesville, FL. *Interfacial Studies of Alkylbenzyltrimethyl ammonium Halides*, April 1972
- Smith Kline & French Laboratories, Philadelphia, PA. *Ways to Enhance Oral Bioavailability*, May 1972
- Albany County Pharmaceutical Association, Albany, NY. *Microencapsulation of Drugs*, April 1973
- 11th Annual Midwest Regional Meeting, IPT Section, Chicago. *In Vitro Dissolution Testing*, October, 1973
- Swedish Academy of Pharmaceutical Sciences, Stockholm. *Dissolution Testing as an Indicator of Bioavailability*, October 1974
- Arden House 10th Education Conference (Faculty member), Harriman, NY. *Bioavailability and Formulation*, January 1975
- IPT Symposium, APHA Meeting, San Francisco, CA. *Dissolution Testing: Today and Tomorrow*, April 1975
- University of Sydney Workshop, Leura, NSW. *Factors Affecting Absorption of Drugs: In Vitro and In Vivo Model Studies*, August 1975
- Royal Australian Chemical Institute, Sydney, NSW. *Recent Advances in Drug Development*, September 1975
- Victorian College of Pharmacy, Melbourne, Vic. *A New Curriculum for Pharmacy*, September 1975
- Australian Society of Cosmetic Chemists, Sydney, NSW. *Formulation of Solubilized and Emulsified Systems*, November 1975
- Society of Hospital Pharmacists of Australia, Sydney, NSW. *Pharmacy Education in the USA*, November 1975
- Association of Health Professions of Australia, Sydney, NSW. *Compulsory Continuing Professional Education*, November 1975
- Royal Australian Chemical Institute, Melbourne, Vic. *New Methods of Drug Delivery*, February 1976
- 29th Congress of the Pharmaceutical Association of Australia and New Zealand, Adelaide, SA. *The Role of the Pharmaceutical Educator in Continuing Professional Education*, April 1976
- 47th Australian and New Zealand Association for the Advancement of Science, Hobart, Tas. *Drug Delivery Systems of the Future*, May 1976
- Pharmaceutical Society of Queensland, Brisbane. *Professional and Continuing Education of the Pharmacist*, May 1976
- Australian Society of Cosmetic Chemists, Sydney, NSW. *Formulation of Controlled Release Preparations*, July 1976
- ICI Americas, Wilmington, Del. *Novel Approaches to Drug Delivery*, August 1976
- International House, London University. *The Role of the Pharmacist in Health Care*, January 1977
- Guild of Hospital Pharmacists, London. *Pre-registration Experience for Pharmacists*, February 1977
- University of Southern California, Los Angeles, CA. *Some Interfacial Phenomena of Pharmaceutical and Biological Significance*, March 1977
- FMC Corporation Meeting, Marbella, Spain. *Rational Formulation of Solid Dosage Forms*, May 1977

**INVITED SPEAKER, SEMINARS PRESENTED (continued):**

- Federation International Pharmaceutique (FIP) Congress, The Hague, The Netherlands, Colloquium on *Professional and Legal Aspects of Drug Selection*, September 1977
- Xth Central American Congress of Pharmaceutical Sciences, San Jose, Costa Rica, *Pharmaceutical Education - Which Way To Go?* October 1977
- University of Panama, Panama City. *Series of four lectures on In Vivo-In Vitro Correlations in Drug Testing*, January 1978
- College of Pharmaceutical Sciences of Panama, Panama City. *New Directions in Pharmacy Education*, January 1978
- Pharmaceutical Society of Great Britain, Epsom Branch. *Relevance of Pharmacy Education in Practice*, March 1978
- Malaysian Pharmaceutical Society, Kuala Lumpur, Malaysia. *Educational Trends in Pharmacy*, March 1978
- Science University of Malaysia, Penang, Malaysia. *Permeation of Phenolic Compounds Through Human Skin*, April 1978
- Association of Teaching Hospital Pharmacists, London. *Trends in Pharmaceutical Education*, May 1978
- American Critical Care Laboratories, Chicago. *Drug Permeation through Human Skin*, June 1978
- New England Respiratory Conference, Hyannis, Mass. *Modern Drug Delivery Systems for Pulmonary Diseases*, July 1978
- Pan American Health Organization Seminar, Panama City, Panama. *The Need for Drug Product Quality Control in Central America*, January 1979
- 1st FMC Seminar West, Los Angeles, CA. *Dissolution Testing - Can We Expect A Solution?* January 1979
- University of Southern California, Los Angeles, CA. *Percutaneous Absorption of Phenolic Compounds*, March 1979
- FMC Industrial Seminar, Montreal and Toronto, Canada. *Dissolution Testing in Product Development*, October 1979
- University of Southern California Continuing Education Program, Alaska Cruise. *Bioavailability and Product Selection by Pharmacists*, July 1979
- Santa Monica Bay Area Pharmaceutical Association, Los Angeles, CA. *Permeation of Drugs Through Human Skin*, August 1979
- ICI Americas, Wilmington, Del. *Percutaneous Absorption as a Method of Drug Delivery*, August 1979
- Syntex Laboratories, Mexico City, Mexico. *The Role of Dissolution Testing in Product Optimization*, October 1979
- Mexican Pharmaceutical Association Meeting, Guanajuato, Mexico. *Bioavailability Studies in Drug Development*, October 1979
- Fisons Pharmaceuticals Ltd., England. *Optimizing the Formulation of Ophthalmic Products*, March 1980
- World Health Organization, Geneva, Switzerland. *Prolonged Release Technologies as Might Be Applied to Dapsone*, THELEP Drug Development Meeting, April 1980
- Fisons Pharmaceuticals Ltd., England. *Prolonging the Action of Orally Administered Drugs*, January 1981
- El Fateh University, Tripoli, Libya. *Bioavailability as a Factor in Quality Control*, March 1981
- IPT Symposium, APhA Meeting, St. Louis, MO. *Organization Within the Pharmaceutical Industry*, April 1981
- Centenary Symposium on Pharmacy Practice, New Zealand Pharmaceutical Society, Auckland, NZ. Plenary lecture on *The Next 100 Years of Pharmacy Practice*, July 1981
- Department of Pharmacy, Central Institute of Technology, Wellington, New Zealand. *Drug Permeation Studies Using Human Skin*, July 1981
- Department of Pharmacy, University of Otago, Dunedin, New Zealand. *Development of Sustained Release Intramuscular Injections*, July 1981



**INVITED SPEAKER, SEMINARS PRESENTED (continued):**

- Burroughs Wellcome Co., Greenville, NC. *Surface Reaction Approach to the Formulation of Sustained Release Forms of Dapsone*, February 1982
- National University of Singapore. *Development of Intramuscular Sustained Release Injection in Leprosy*, March 1982
- Pharmaceutical Society of Singapore. *New Approaches to Drug Delivery*, April 1982
- Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. *Permeation of Drugs Through Human Skin*, April 1982
- Burroughs Wellcome Co., Greenville, NC. *Percutaneous Absorption in Man*, December 1982
- Fisons plc, Pharmaceutical Division, Loughborough, England. *Effect of Lipophilic Vehicle on the Disposition of Sodium Cromoglycate in the Rabbit Eye*, April 1983
- Fisons plc, Pharmaceutical Division, Loughborough, England. *Studies on the Percutaneous Absorption of Chromone-2-carboxylic Acids and Esters*, July 1983
- Society of Cosmetic Chemists, Carolina Chapter, Raleigh NC. *Factors Affecting Percutaneous Absorption*, September 1984
- Fisons plc, Pharmaceutical Division, Loughborough, England. *Fluidization and Dosage Form Design and Performance*, February 1985
- Course on *Principles of Emulsion and Suspension Technology*, UNC School of Pharmacy, February 1985. Course Director and Lecturer
- Astra Pharmaceutical Company, Sodertalje, Sweden. *Novel Approaches to Sustained Release and Factors Influencing Transport of Drugs through Skin*, April 1985
- Sterling-Winthrop Research Center, Alnwick, England. *Percutaneous Absorption of Ionizable Compounds*, May 1985
- Family Health International, Expert meeting on *Development of Spermicides*, Raleigh, NC. *Formulation Approaches*, December 1985.
- Greater Raleigh Pharmaceutical Discussion Group, Zebulon, NC. *Bridging the Gap between Product Development and Production*, February 1986
- Pharmaceutical Manufacturers Association (Production, Engineering, and Materials Management Section), *Production Symposium*, Raleigh, NC. April 1986
- PharmTech Conference, Cherry Hill, NJ. Session Chairman for *Contracting Outside Services and Skills*, September 1986
- Pharmacy Practice Seminar Series, UNC, Chapel Hill. *The Role of Basic Science in the Pharmacy Curriculum*, March 1987
- Family Health International, Research Triangle Park, N.C. *Formulation Development of Vaginal Delivery Systems*, July 1987
- Pharm. Tech. Conference, The Meadowlands, N.J. Session Chairman for *Effervescence: The Underutilized Technology*, September 1987
- North Carolina Pharmaceutical Discussion Group, Wilson, N.C. *Transdermal Drug Delivery*, November 1987
- Interpharm Conference, U.K. *Industry-University Collaborations in the USA*, May 1988
- South African Congress of Pharmaceutical Sciences, (plenary lecture) *Transdermal Drug Delivery*; Port Elizabeth, South Africa *The Funding of Research in the Pharmaceutical Sciences* (Banquet speech), May 1988
- University of the Western Cape, Cape Town, South Africa *Controlled Drug Release*, May 1988
- Radio South Africa *Drug Delivery to the Lung and Vagina*, May 1988
- School of Pharmacy, Rhodes University, Grahamstown, South Africa *Effect of Drugs on Mucus*" May 1988
- Department of Pharmacy, University of Pretoria, Pretoria, South Africa *Viscoelasticity of Mucus*, June 1988
- Medical University of Southern Africa, Medunsa, South Africa *Effect of Drugs on Viscoelasticity of Mucus*, June 1988

**INVITED SPEAKER, SEMINARS PRESENTED (continued):**

- Department of Pharmacy, Potchefstroom University, Potchefstroom, South Africa  
*Physicochemical Properties of Mucus*, June 1988
- Brighton Polytechnic, U.K., *Hydration and Dehydration of Mucus*, July 1988
- College of Pharmacy Practice, London, U.K., *American Pharmacy Undergraduate Courses and Their Products*, July 1988
- PharmTech Conference, Philadelphia, PA, *Scientific Manuscript Writing and Organization or How to Make It To The Best Seller List!*, September 1989
- North Carolina Pharmaceutical Discussion Group, Chapel Hill, NC, *The Promise and Potential of Biotechnology*, October 1989
- PharmTech Conference, New Brunswick, NJ, *Bridging the Interface between Product Development and Production*, September 1990
- Shanghai Medical University, People's Republic of China, Two lectures on *Controlled Drug Release and Effect of Mucus on Drug Delivery*, April 1991
- Shanghai Pharmaceutical Society, Shanghai, People's Republic of China, *Transdermal Drug Delivery*, April 1991
- Shanghai Institute of Pharmaceutical Technology, Shanghai, People's Republic of China, *Formulation of Modern Pharmaceutical Products*, April 1991
- Faculty of Pharmacy, National University, Mexico City, Mexico. *Non-Device Approaches to Controlled Release*, June 1991
- Instituto Tecnológico de Estudios Superiores de Monterrey, Mexico City, Mexico. 12 hour lecture course on *Aspects of Controlled Drug Release* for Diplomado en Tecnología Farmacéutica, June 1991
- First International Symposium on Applied Chemistry, Instituto Tecnológico de Estudios Superiores de Monterrey, Monterrey, Mexico. *Physico-Chemical Factors Affecting Drug Activity*, October, 1991
- School of Pharmacy, University of Wisconsin - Madison. *Teaching, Research and Service in a Professional Program within a Research University*, November, 1991.
- AAPS 5th Annual Meeting, Washington, D.C., *Computer Assisted Drug Design and Selection*, PDD/MNPC Joint Symposium, November 1991.
- School of Pharmacy, University of North Carolina at Chapel Hill. *The Pursuit of Excellence and Balance in Teaching, Research and Service at a Professional School in a Research-Intensive University*, December 1991.
- Arden House Conference, Harriman, NY. *Do Processing and Scale-Up Factors Really Affect Bioavailability?*, January 1992
- Pharm Tech '92 Conference, East Brunswick, NJ. *Pharmaceutical Aerosols and Inhalation Products*, September 1992.
- AAI Annual Development Seminar, Wilmington, NC. *Good Development Practices -- A Concept Whose Time Has Come?*, June 1993.
- Fourteenth Annual Congress of the South African Academy of Pharmaceutical Sciences, Durban, South Africa. Plenary Lecture on *Drug Distribution in the Skin: An In Vitro-In Vivo Comparison using Estradiol as a Model Compound*, June 1993.
- 34th Symposium of Associazione Farmaceutica Industria (AFI), Venice, Italy. *Advances in Controlled Drug Delivery*, May, 1994.
- PharmTech '95 Conference, East Brunswick, NJ. *Problems Associated with the Use of Bulk Drug Chemicals*, September, 1995.
- Nova Nordisk, Copenhagen, Denmark. *Good Formulation Development Practices*, November 1995.
- Associazione Farmaceutica Industria (AFI) Seminar, Milan, Italy. *Good Formulation Development Practices*, November 1995.
- Tablet Manufacturing Conference, Techsource, Atlantic City, NJ. *Preparation of Low Dose Oral Solid Dosage Forms*, May 1996.

**INVITED SPEAKER, SEMINARS PRESENTED (continued):**

- Twenty Fifth InterPharm Research Conference, Weston on the Green, UK. *Outsourcing – An American View*, May 1997.
- Fourth Annual PharmTech Conference Puerto Rico, Rio Grande, PR. *Change-Induced Problems in Tablet Manufacture – and Supac-IR*, June 1997.
- Twenty Sixth InterPharm Research Conference, Usk, South Wales, UK. *Enhanced Absorption using ProSorb Technology*, May 1998.
- Compliance and Validation Issues "98", Techsource, Atlantic City, NJ. *SUPAC Guidelines -- Important Keys to Compliance*, June 1998.
- PhRMA Foundation Annual Awardee Meeting, New York, NY. *The Role of Rapidly Absorbed Non-Steroidal Anti-Inflammatory Agents in the Abortive Treatment of Migraine*, April, 1999.
- Twenty Seventh InterPharm Research Conference, Usk, South Wales, UK. *SUPAC -- From Concept to Formulation Tool*, May 1999.
- International Business Communications' (IBC's) 3<sup>rd</sup> Annual Conference on Migraine -- Novel Drug and Therapeutic Development, Philadelphia, PA. *ProSorb<sup>TM</sup> Technology Creates Rapid Absorption of NSAIDs Used in the Treatment of Migraine*, May 1999.
- AAPS Southeast Regional Meeting, Durham, NC. Plenary Lecture on *The Role of Contract Research and Product Development Organizations in the Drug Development Process*, June 1999.